0 Items
Select Page

Borrelia burgdorferi

B. burgdorferi infection can cause the condition known as Lyme disease or Lyme borreliosis. In humans, the most common clinical manifestation of infection is a large red rash (erythema migrans), which varies in its size and appearance, and generally resolves without treatment.

The Native Antigen Company provides monoclonal antibodies specific to B. burgdorferi, ideal for use in a range of immunoassays.

Borrelia Background

The Borrelia burgdorferi species belongs to the Borrelia burgdorferi sensu lato species complex of spirochetes. B. burgdorferi is a member of the genus Borrelia of the family Spirochaetaceae. In nature, spirochetes are maintained in a transmission cycle between hard ticks of the Ixodes species and a reservoir of small-medium sized vertebrate, and in some cases birds. In humans, infection occurs through the bite of a tick infected with the spirochete. Infection with B. burgdorferi in humans can cause a condition known as Lyme disease or Lyme borreliosis. Five Borrelia species have been reported to infect humans, including B. burgdorferi sensu stricto in North America and Europe, B. garinii, B. bavariensis, B. afzelii in Europe and Asia, and B. spielmanii in Europe. B. afzelii and B. garinii account for most cases of Lymes disease in Europe (Wang, G.), which are transmitted by the hard tick Ixodes Ricinus and maintained in small vertebrates and birds.

In humans, the most common clinical manifestation of infection is a large red rash, referred to as erythema migrans, which can vary in size and appearance. Additional symptoms include fever, chills, headache, fatigue, joint pains and swollen lymph nodes. However, in some severe cases, the infection may spread to joints, the nervous system or heart and clinical symptoms including neck stiffness, arthritis, facial palsy, heart palpitations, nerve pain, numbness and memory loss may develop (CDC). Erythema migrans generally resolves without treatment. However, patients with Lyme disease are often treated with antibiotics to prevent dissemination and potential development of more severe clinical symptoms. Currently, no licensed vaccine to prevent Borrelia burgdorferi infection is available.

References

  1. Wang G, Liveris D, Mukherjee P, Jungnick S, Margos G, Schwartz I. 2014. Molecular Typing of Borrelia burgdorferi. Curr Protoc Microbiol. Aug 1;34:12C.5.1-31
  1. Centers for Disease Control and Prevention: Lyme Disease

 

Borrelia Antigens

We offer an extensive range of Borrelia borgderferi antigens, expressed as recombinant proteins in E. coli.

These antigens are suitable for use in assay development, vaccine research and as antigens for the preparation of Borrelia-specific antibodies.

Borrelia Immunoassays

We are pleased to offer ELISA assays for the detection of antibody response (IgG and IgM) to Borrelia borgderferi. These assays are suitable for use in laboratory research and development activities and vaccine research studies.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Zika Prevalence in Suriname – an insight into assay cross-reactivity

A recent study published by Langerak et al tested for the seroprevalence of Zika virus in Suriname populations and evaluated the comparative effectiveness of using a commercial ELISA and a standard Virus Neutralisation Assay. Here we discuss the study, its results,...

What should you call your favourite virus?

The International Committee on Taxonomy of Viruses (ICTV) meet regularly to ensure the taxonomy of viruses is kept logical and up-to-date in the face of an ever-increasing number of new viruses and genome sequences; discussed in here in Nature. This sometimes results...

Overcoming Zika-Dengue cross-reactivity: the highly specific immunoassays your lab needs

In the global battle against Zika virus, serological cross-reactivity with Dengue is a major challenge for academics, epidemiologists and pharmaceutical companies alike. Novel immunoassays can now overcome this problem and could prove a real game-changer in Zika...

The Right Tools for Rubella

Rubella remains a significant pathogen worldwide, with 100,000 cases of congenital rubella syndrome estimated to occur every year. Vaccines to Rubella are highly safe and have effectively eliminated endemic infection in many developed countries, yet inadequate...

Visualising viral infection with immunofluorescence microscopy

Following the latest immunofluoresence data for our Zika and Dengue antibodies, we’ve invited VRS to write a short blog one of their areas of expertise: The applications of immunofluorescence microscopy in studying viruses.   A lot of what we know about biology...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

14 + 2 =

Live Customer Feedback